AUTHORS
David J Kuter, MD, DPhil, Caroline Piatek, MD2, Joan Cid, MD, PhD3, Michael Fillitz4, Huyen Tran, MBBS5, Lixia Wang, PhD6, Abraham Fong, MD, PhD7, Alexander Röth, MD8
AFFILIATIONS
1 Hematology Division, Massachusetts General Hospital, Boston, Massachusetts, United States
2 Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles, California, United States
3 Apheresis and Cell Therapy Unit, Hospital Clínic de Barcelona, Barcelona, Spain
4 3rd Department of Medicine, Center for Haematology and Oncology, Hanusch Hospital, Vienna, Austria
5 Haemostasis Thrombosis Unit, Alfred Hospital, Melbourne, Victoria, Australia
6 Biometrics and Data Sciences, Rigel Pharmaceuticals, Inc, South San Francisco, California, United States
7 Clinical Development, Rigel Pharmaceuticals, Inc., South San Francisco, California, United States
8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany
ABSTRACT
Background
Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disease characterized by immune-mediated red blood cell destruction that can result in chronic hemolytic anemia, fatigue, and substantial morbidity. Many patients experience persistent or recurrent hemolysis despite therapy. Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor that targets Fc receptor-mediated destruction of antibody-coated red blood cells. In a phase 3 trial of fostamatinib in wAIHA (NCT03764618), 35.6% of patients achieved a durable hemoglobin response versus 26.7% on placebo (p=0.398). A regional post hoc analysis revealed a substantial placebo response in Eastern Europe, and a reanalysis demonstrated a significantly higher durable hemoglobin response with fostamatinib among patients from North America, Australia, and Western Europe compared with placebo (32.0% vs 0%, p=0.0021).1 Here, we evaluate the long-term efficacy and safety of fostamatinib in the open-label long-term extension (LTE) (NCT04138927).
Methods
Patients who completed the Phase 3 study were eligible to enter the LTE and receive fostamatinib. The LTE was terminated early due to Sponsor decision. Stable background wAIHA therapies were permitted throughout the study. Durable hemoglobin response was defined as achievement of a hemoglobin level ≥10 g/dL with an increase from baseline of ≥2 g/dL on 3 consecutive available visits during the 24-week treatment period. Durable response rates were assessed at Week 24 among patients randomized to fostamatinib in the Phase 3 study and placebo-treated patients who subsequently received fostamatinib in the LTE. Long-term durability of response was evaluated in all patients through Week 104. Safety outcomes included treatment-emergent adverse events (TEAEs), serious TEAEs, treatment-related TEAEs, dose modifications, dose interruptions, and treatment discontinuations due to TEAEs.
Results
Seventy-one patients enrolled in the LTE (38 previously randomized to fostamatinib and 33 to placebo). Mean age was 59.0 years and 61.4% were female. Baseline mean hemoglobin was 10.3 g/dL in both groups. Sixteen completed the study and 55 discontinued during follow-up.
24-week durable response rates were similar between patients who initially received fostamatinib and those who crossed over to fostamatinib from placebo in the LTE. Among patients randomized to fostamatinib in the Phase 3 study, the 24-week durable response rate was 35.6% (16/45; 95% confidence interval [CI], 21.9-51.2). Among patients randomized to placebo who subsequently received fostamatinib in the LTE, the 24-week durable response rate was 31.1% (14/45; 95% CI, 18.2-46.6).
During the LTE follow-up through Week 104, durable hemoglobin response rates were 52.6% (20/38; 95% CI, 35.8-69.0) among patients treated with fostamatinib throughout the Phase 3 and LTE studies and 60.6% (20/33; 95% CI, 42.1-77.1) among patients who switched from placebo to fostamatinib in the LTE study. Among durable responders, median duration of response was 280.0 and 183.0 days, respectively.
No new safety signals were identified. In the LTE safety population (N=70), 66 patients (94.3%) experienced ≥1 TEAE, 23 (32.9%) experienced ≥1 serious TEAE, and 33 (47.1%) experienced ≥1 treatment-related TEAE. TEAEs led to dose interruption in 17 patients (24.3%), dose modification in 21 (30.0%), and treatment discontinuation in 16 (22.9%). Eight deaths (11.4%) were reported during the LTE, none of which were related to fostamatinib. Common adverse events included diarrhea (27.1%), hypertension (20.0%), and neutropenia (14.3%).
Conclusions
Durable hemoglobin response rates were similar among patients who received fostamatinib during the Phase 3 study and those who switched from placebo to fostamatinib in the LTE, supporting the potential utility of fostamatinib in patients with wAIHA. Durable hemoglobin response rates showed a numerical increase through Week 104 and were consistent with prior clinical studies and real-world evidence. The long-term safety profile was consistent with the established safety profile of fostamatinib, with no new safety findings identified during long-term follow-up.
Kuter DJ, et al. Am J Hematol. 2024; 99: 79–87.
DISCLOSURES
David J Kuter, MD, DPhil: HUTCHMED - Research Funding; Sanofi - Research Funding; Fulcrum Therapeutics - Research Funding; Principia Biopharma - Research Funding; Novartis - Research Funding; Takeda - Research Funding; UCB - Consultancy (Includes expert testimony); Actelion - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Immunovant - Consultancy (Includes expert testimony); CVS Caremark - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Kyowa Kirin - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BioCryst - Consultancy (Includes expert testimony); Principia Biopharma - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); HUTCHMED - Consultancy (Includes expert testimony); UpToDate - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Hengrui Pharmaceutical - Consultancy (Includes expert testimony); Genzyme - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Chugai Pharma - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Verve - Consultancy (Includes expert testimony); Crico - Consultancy (Includes expert testimony); Platelet Disorder Support Association - Consultancy (Includes expert testimony); Alexion Pharmaceuticals - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)